You are here

Generic Version of Glucophage Approved by FDA

PITTSBURGH, Sept. 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Metformin Hydrochloride Extended-release Tablets, 500 mg and 750 mg. Metformin HCl ER Tablets, which are the generic version of Bristol-Myers Squibb's Glucophage(R) XR Tablets, 500 mg and 750 mg, had U.S. sales of approximately $173 million, for the 12-month period ending June 30, 2005, according to IMS.

This product will be available soon.

Source: Mylan Laboratories Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks